You are hereJuly 23, 2018
What’s the Stem Cells Buzz this Week? - Astrocytic Gene Hydroxymethylation, Facilitating Cells, Megakaryocyte-induced Myeloproliferation, and a Regenerative Medicine Roadmap!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
DNA Hydroxymethylation of Astrocytic Genes in Neural Stem Cells
Following studies that indicated that vitamin C promotes DNA hydroxymethylation and transcription of dopamine neuron‐specific genes and the differentiation of neural stem cells (NSCs) into dopamine neurons, researchers from the labs of (Hanyang University, Seoul, South Korea) and (KRIBB, Daejeon, South Korea) set out to discover more. Kim et al. now describe how vitamin C promotes the DNA hydroxymethylation and transcription of astrocyte‐specific genes and astrocyte differentiation and so may be essential to astrocytogenesis during brain development. See now for more details.
The Role of Flt3-ligand in the p‐preDC FC Subpopulation
Facilitating cells (FC), which resemble plasmacytoid precursor dendritic cells (p‐preDC), enhance engraftment of purified hematopoietic stem cells (HSC) and induce antigen‐specific regulatory T cells (Treg) in vivo. The lab of (University of Louisville, Louisville, KY, USA) now reports the Flt3‐ligand as a critical growth factor in the development and homeostasis of p‐preDC FC and the generation of Treg. Huang et al. suggest that the Flt3‐ligand provides potent immunoregulatory properties that may be clinically useful to improve tolerance induction and enhance the function of allogeneic cell therapies. Head over to now for a deeper dive into this new study.
Mutation-carrying Megakaryocyte-induced Myeloproliferation
Researchers from the lab of (Stony Brook School of Medicine, NY, USA) recently sought to discover how the acquired kinase mutation JAK2V617F promotes hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of mature blood cells in myeloproliferative neoplasms (MPNs). Zhang et al. now report that JAK2V617F‐bearing megakaryocytes induce HSPC quiescence with increased repopulating capacity via thrombopoietin and its receptor MPL. The authors suggest that targeting HSPC niche‐forming megakaryocytes and their interactions within the vascular niche could provide a novel and effective therapeutic strategy in patients with MPNs. See now for more!
Roadmap for Manufacturing in Regenerative Medicine
A new Perspective article from , , and (Wake Forest University, Winston‐Salem, NC, USA) in details on the achievement of a “roadmap” to provide the access for those in need to regenerative medicine therapies, both within the United States and around the World. The authors hope that technical advancements in the seven clinical manufacturing impact areas will accelerate clinical translation of regenerative medicine‐based therapies, and facilitate the scale‐up in clinical manufacturing capacity required for deployment of these therapies to the vast number of patients that would benefit from them.
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!